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OBJECTIVE: To verify whether the capacity of high-density lipoprotein (HDL) to simultaneously receive non-
esterified cholesterol, triglycerides, cholesteryl esters, and phospholipids changes with aging and the presence of
coronary artery disease.
DESIGN: Cross-sectional study with biochemical analyses.
SUBJECTS: Eleven elderly patients with coronary artery disease (74¡5 years) were compared with the following
groups of non-coronary artery disease subjects (referred to as ‘‘healthy’’): 25 young (25¡5 years), 25 middle-aged
(42¡6 years), and 25 elderly subjects (75¡8 years).
METHODS: Plasma samples were incubated with a nanoemulsion labeled with radioactive lipids; the transfer of the
lipids from the nanoemulsion to the HDL was measured in chemically precipitated HDL. HDL size and paraoxonase-1
activity were also determined.
RESULTS: The transfer of cholesteryl esters and phospholipids to high-density lipoprotein was significantly greater
(p,0.001) in healthy elderly subjects than in the middle-aged and younger subjects. Non-esterified cholesterol and
triglyceride transfer was not different among these three groups. The HDL size was significantly greater (p,0.001) in
healthy elderly subjects than in the middle-aged and younger subjects. The paraoxonase-1 activity was similar among the
groups. Compared with healthy elderly subjects, coronary artery disease elderly subjects had significantly less (p,0.05)
transfer of non-esterified cholesterol, triglycerides, and cholesteryl esters to the HDL and a significantly smaller (p,0.05)
HDL size.
CONCLUSION: Because lipid transfer is enhanced in healthy elderly subjects but not in those with coronary artery
disease, increasing lipid transfer to HDL may be a protective mechanism against the disease.
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INTRODUCTION
Both the high-density lipoprotein (HDL) cholesterol
concentration in the plasma and the concentration of the
main HDL apolipoprotein, apo A1, negatively correlate with
the incidence of coronary artery disease, and both are
biomarkers of healthy aging.1-4 Data from the Prospective
Cardiovascular Mu¨nster (PROCAM) study have shown that
having a low HDL cholesterol level was the predominant
characteristic of subjects older than 60 years with a history
of myocardial infarction compared to subjects older than 60
years without previous cardiovascular events.4
The HDL fraction is composed of heterogeneous particles
with sizes ranging from 7 to 14 nm.1,5 In addition to its roles
in reverse cholesterol transport and cholesterol esterifica-
tion, HDL has antioxidant activity that is mostly due to its
association with paraoxonase 1 (PON 1) and anti-inflam-
matory, antithrombotic, and vasodilation activities that may
account for the antiatherogenic action of the lipoprotein.6,7
Nascent HDL is produced in the liver and intestine as
discoid particles composed of phospholipids and non-
esterified cholesterol. These particles are progressively
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transformed into a spherical shape by the acquisition of
lipids and the esterification of cholesterol by lecithin-
cholesterol acyltransferase (LCAT), with apo A1 as a
cofactor. Because most of the apo A1 that is present in the
plasma is contained in the HDL fraction and because LCAT
is also associated with HDL, cholesterol esterification occurs
mainly in this lipoprotein fraction.7 HDL is thus constantly
being remodeled, and lipid transfers are essential for the
roles of this lipoprotein in cholesterol esterification and
reverse cholesterol transport. Both processes are intertwined
and are necessary for cholesterol homeostasis. Lipid
transfers between lipoprotein classes are bidirectional and
depend on the structures of the donor and acceptor
lipoproteins and the activity of the transfer proteins, i.e.,
cholesteryl ester transfer protein (CETP) and phospholipid
transfer protein (PLTP). The concentrations of the donor
and acceptor lipoprotein classes may also influence the
process.8-11
Because the lipid transfer process is a determinant of HDL
composition and metabolism, it is also possible that in
addition to the HDL function in reverse cholesterol
transport, other atheroprotective functions of the lipopro-
tein may be affected by this process. The current study was
designed to verify the effects of aging on the capacity of
HDL to simultaneously receive cholesteryl esters (CEs),
phospholipids (PLs), triglycerides (TGs), and non-esterified
cholesterol (NEC). A standard artificial nanoemulsion was
used as the donor of radioactive lipids to HDL in an in vitro
assay12 with plasma from subjects within different age
ranges: young, middle-aged, and elderly subjects. The HDL
size and PON 1 activity were also measured. A group of
elderly patients with coronary disease was also studied to
investigate whether a different pattern of lipid transfer to
HDL was associated with the disease.
METHODS AND MATERIALS
Study subjects
The volunteer participants in the study were recruited at
the outpatient clinics and at the Division of Geriatric
Cardiology of the Heart Institute of the Medical School
Hospital of the University of Sa˜o Paulo, where they were
referred for routine check-ups and clinical and laboratory
tests and were pronounced healthy. Three groups of
subjects paired for gender and body mass index (BMI) were
studied: young (aged 20-25 years; 10 men and 15 women),
middle-aged (aged 39-54 years; 9 men and 16 women), and
elderly (aged 65-82 years; 11 men and 14 women) subjects.
A fourth group (aged 65-81 years; 5 men and 6 women) was
composed of 11 elderly patients with coronary artery
disease (CAD). The presence of CAD was confirmed by
coronary angiography performed within six months prior to
the study. None of the participants were smokers; obese;
alcoholics; or had liver, renal, metabolic, inflammatory, or
neoplastic disease. Their physical characteristics and plasma
biochemical parameters are shown in Table 1. All of the
patients in the non-CAD elderly and CAD elderly groups
were receiving standard maintenance hypertension treat-
ment with a beta-adrenergic blocker or an angiotensin-
converting enzyme (ACE) inhibitor. The elderly CAD
subjects were also taking statin medications, which were
discontinued for at least 30 days before the study.
The Ethics Committee of the Medical School Hospital of
the University of Sa˜o Paulo approved the study, and written
informed consent was obtained from all of the subjects
following a complete description of the protocol.
Plasma lipids and apolipoproteins
Plasma total cholesterol (CHOD-PAP; Roche, Basel,
Switzerland) and triglyceride (Triglyceride Rapid; Roche)
levels were determined by enzymatic methods using a
Cobas Bio analyzer (Roche, Basel, Switzerland). HDL
cholesterol was measured using the same method used for
total cholesterol after lipoprotein precipitation with magne-
sium phosphotungstate. The low-density lipoprotein (LDL)
cholesterol level was estimated with the Friedewald
formula.13 Apo A1 and apo B levels were determined using
an immunoturbidimetric assay (Roche) on a Cobas MIRA
analyzer.
Nanoemulsion preparation
The lipid donor nanoemulsion was prepared from a
lipid mixture composed of 40 mg cholesteryl oleate, 20 mg
egg phosphatidylcholine, 1 mg triolein, and 0.5 mg cho-
lesterol, all purchased from Sigma Chemical Company (St.
Louis, MO). The lipids were emulsified by prolonged
ultrasonic irradiation in aqueous media and a two-step
ultracentrifugation of the crude emulsion with density
adjustment by addition of KBr to obtain the nanoemulsion,
as previously described.14,15 The nanoemulsion fraction
was dialyzed against a 0.9% NaCl solution. Trace amounts
of [12, 2d(n)-3H]-cholesteryl oleate and glycerol tri[9,
10(n)-3H] oleate or 4-14C-cholesterol and L-3-phosphati-
dylcholine, 1-stearoyl-2-[1-14C] arachidonyl. (Amersham,
Little Chalfont, Buckinghanshier, UK) were added to the
initial solution.
Lipid transfer from the nanoemulsion to HDL
This assay was previously described by Lo Prete et al.12 In
brief, the nanoemulsion labeled with 3H-CE and 14C-PL or
with 14C-NEC and 3H-TG was incubated with whole plasma
followed by chemical precipitation of the apo B-containing
lipoproteins and the nanoemulsion. The supernatant con-
taining the lipids that shifted from the nanoemulsion to the
HDL was then measured for radioactivity in a scintillation
solution. The results of the radioactive transfer from the
nanoemulsion to the HDL were expressed as the percentage
Table 1 - Physical characteristics and plasma biochemical
parameters of the study subjects.
Parameters
Young
(n =25)
Middle-aged
(n = 25)
Elderly
(n = 25)
CAD Elderly
(n = 11)
Age (years) 25¡5 42¡6 75¡8* 74¡5
Gender (M/F) 10/15 9/16 11/14 5/6
BMI (kg/m2) 26¡4 25¡5 27¡3 26¡4
Cholesterol
Total (mg/dL) 113¡18 173¡43 190¡40* 201¡30
HDL (mg/dL) 41¡6 40¡7 50¡12* 42¡6**
LDL (mg/dL) 96¡23 102¡44 104¡19 143¡25**
Triglycerides (mg/dL) 86¡15 100¡20 101¡30 123¡46
Apo A1 (mg/dL) 128¡30 135¡14 141¡40 100¡60
Apo B (mg/dL) 70¡18 88¡15 80¡15 87¡40
The data are expressed as the means ¡ S.D.;
*p,0.001 when compared to the young and middle-aged groups;
**p,0.05 when compared to the non-CAD elderly group. BMI, body mass
index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; apo
A1, apolipoprotein A1; Apo B, apolipoprotein B.
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of the total incubated radioactivity found in the HDL-
containing supernatant.12
PON 1 activity
PON 1 activity was assayed using 12-h fasting blood
serum, according to the method described by Mackness
et al.,16 by adding serum to Tris-HCl buffer (100 mmol/L,
pH 8.0) containing 2 mmol/L CaCl2 and 1.1 mmol/L
paraoxon (0,0-diethyl-0-p-nitrophenylphosphate; Sigma).
The rate of generation of p-nitrophenol was determined at
37 C˚ with the use of a spectrophotometer at 405 nm.
HDL diameter
The HDL size was measured by use of a ZetaPALS zeta
potential analyzer (Brookhaven Instruments, Holtsville,
NY), as previously described.17
Statistical analyses
A power calculation indicated that, with n.23 in each
group, we would have 80% power (at a significance level of
0.05) to detect a difference in lipid transfer values between
the study groups. The differences between the results were
evaluated using analysis of variance (ANOVA) and
Student’s t-test. Significant correlations were identified
using ANOVA and Pearson’s test. In all of the analyses, a
difference of p,0.05 was considered statistically significant.
The data are expressed as the means¡ standard deviations.
GraphPad Prism version 3.0 was used to assist with the
analyses.
RESULTS
Table 1 shows the plasma lipid and apolipoprotein
concentrations of the study subjects. The HDL cholesterol
levels were greater in the non-CAD elderly than in the
middle-aged and young subjects (p,0.001) but did not
differ between the young and middle-aged groups. The LDL
cholesterol, triglycerides, apo A1, and apo B levels were not
different among these three groups. In the CAD elderly
group, the HDL cholesterol level was higher and the LDL
cholesterol level was lower than in the non-CAD elderly
group (p,0.001).
Table 2 shows that the non-CAD elderly group had larger
HDL particles when compared with the middle-aged and
young subjects. The CAD elderly group had smaller HDL
particles than the non-CAD elderly group. The PON 1
activity was similar among the four groups.
Table 2 also shows the transfer of the four lipids from the
artificial nanoemulsion to the HDL fraction. The transfer of
CE and PL was greater in the non-CAD elderly subjects
than in the middle-aged and young subjects (p = 0.0368),
whereas the latter two groups did not differ in the transfer
of CE or PL. The NEC and TG transfer rates were equal in
these three study groups. Compared with the non-CAD
elderly group, the CAD elderly had decreased transfer of
NEC, TG, and CE to HDL (p,0.001), but the PL transfer
was equal.
The CE, TG, and NEC transfers were positively correlated
with each other. In contrast, the PL transfer correlated
positively with the CE transfer but showed no correlation
with the TG or NEC transfer. With respect to the correlation
analysis of the lipid transfer values versus the physical
characteristics and laboratory data of the subjects, positive
correlations were found between age and the CE transfer and
between HDL cholesterol, cholesterol total concentration and
HDL size, as shown in Figure 1. No correlation was found
between age and the TG, PL, or NEC transfer. The PL transfer
correlated positively with the HDL cholesterol level, whereas
the NEC, CE, and TG transfers did not. With respect to other
plasma lipids, a positive correlation was found between the
TG transfer and the apo B concentration. No correlation was
found between the CE, PL, NEC, or TG transfer and the total,
LDL or very-low-density lipoprotein (VLDL) cholesterol or
TG. The transfer of the four lipids did not correlate with the
plasma glucose level or the patient’s BMI.
DISCUSSION
In this study, the group of non-CAD elderly subjects
showed greater transfers of CE and PL and larger HDL
particle sizes than did the middle-aged and young subjects.
In the CAD elderly subjects, less CE, TG, and NEC was
transferred, and the HDL particle size was smaller than in
the non-CAD elderly subjects. These novel observations
were obtained by means of the in vitro method recently
described by Lo Prete et al.,12 in which the simultaneous
transfer of all four main lipids is tested, specifically focusing
on HDL and measuring the particle size of the entire HDL
fraction using laser light scattering.17
In reverse cholesterol transport, cholesterol from the
peripheral tissues is transported by HDL and taken up by
the SR-B1 receptors in the liver, together with the HDL
particles.18 Alternatively, HDL cholesterol is transferred to
other lipoprotein classes, such as VLDL and VLDL catabolic
products, such as LDL, that are taken up together by the
liver, which excretes the lipoprotein cholesterol content into
the bile. During this process, the transfer proteins play a
major role. CETP and PLTP are the major proteins involved
in these lipid shifts. CETP specifically mediates the transfer
of cholesteryl esters and triglycerides and is associated with
HDL in the plasma.19 In contrast, PLTP facilitates the
transfer of surface phospholipids from other lipoproteins to
HDL and influences HDL remodeling by promoting the
formation of larger HDL particles, such as HDL2b and
HDL2a, at the expense of the small subfraction HDL3 (see
ref. 20 for a review). Lipid transfers between lipoprotein
classes are bidirectional but frequently result in lipid
enrichment or the depletion of lipid species of a given
lipoprotein class.7,21 Cholesterol is stored in cells in its
esterified form. After the hydrolysis of CE by cytoplasmic
esterases, NEC is transferred from cells to HDL by the
ABCA1 system, which comprises membrane transporters
that mediate the efflux of NEC and PL to HDL.22 The
cholesterol from peripheral tissues transported in HDL can
be transferred to the other lipoproteins by CETP or be taken
up by hepatic SR-B1 receptors.22 Both the ABCA1 system
and the SR-B1 receptors, which were not evaluated here, are
thus important contributors to the continuously changing
HDL composition and may have influenced the results of
the lipid transfer assay in this study.
Both the concentration of HDL in the plasma and the
qualitative and functional aspects of this lipoprotein are
important for its anti-atherogenic actions.23,24 Patients whose
HDL contains the apo A1 Milano mutation exemplify a
population that is protected from cardiovascular events
despite low levels of circulating HDL. Similarly, individuals
with high levels of HDL that is prone to modification may be
less protected than individuals with average levels of HDL
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that is more resistant to modification.9 The capacity to receive
lipids is a fundamental feature of HDL because the metabo-
lism and function of this lipoprotein in the reverse cholesterol
transport fundamentally depend on lipid exchanges.25
In the in vitro assay with whole plasma used in this study,
many factors may have influenced the transfer of lipids from
the standard donor nanoemulsion to HDL, such as the
concentration, composition, and structure of both the HDL
and the other acceptor lipoprotein classes, which contain apo
B. The latter lipoproteins compete with HDL to receive lipids
from the nanoemulsion and may thus influence the HDL
lipid acceptance results. CETP and PLTP are paramount in
this process because they facilitate the transfer of the lipids.
The concentration of apo B, which is present in LDL and
VLDL and LDL cholesterol, was not different among the
study groups, but the HDL cholesterol level, which was
higher in the non-CAD elderly, could have influenced the
transfer results, which would favor an increase in lipid
acceptance by HDL. There are no consistent reports in the
literature on the effect of aging on the action of transfer
proteins.
An increase in core lipids, such as CE, may increase the
size of the particles,24 as was found in this study in the
elderly group. The increase in the PL transfer found in the
Table 2 - The transfer of lipids from the artificial
nanoemulsion to HDL, HDL size and PON1 activity in the
study subjects.
PARAMETERS
Young
(n =25)
Middle-aged
(n =25)
Elderly
(n = 25)
CAD Elderly
(n = 11)
Lipid transfers (%)
Non-esterified
cholesterol
9.6¡1.7 10.1¡1.2 10.0¡2.4 8.2¡1.3**
Cholesteryl ester 3.7¡1.0 4.1¡0.7 5.3¡1.8* 3.1¡2.3**
Triglycerides 6.5¡ 1.3 6.9¡1.3 7.3¡2.4 5.1¡1.6**
Phospholipids 18.7¡4.6 18.3¡4.0 20.6¡5.3* 19.9¡2.3
HDL diameter (nm) 8.9¡ 0.3 8.9¡ 0.3 9.7¡ 1.6* 8.7¡0.7**
PON 1
(nmol min-1 mL-1)
97¡ 44 85¡ 40 85¡ 44 76¡42
The data are expressed as the means ¡ S.D.;
*p,0.001 when compared to the young and middle-aged groups;
**p,0.05 when compared to the non-CAD elderly group. HDL, high-
density lipoprotein; PON 1, paraoxonase 1. The transfer of lipids from
the donor nanoemulsion to HDL is expressed as the % of the total
radioactivity from the whole plasma that was recovered in the HDL
fraction after chemical precipitation of the apo B-containing
lipoproteins and the nanoemulsion.
Figure 1 - Correlations between age and HDL cholesterol (A), total cholesterol (B), HDL size (C), and the transfer of cholesteryl esters (D).
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non-CAD elderly group should favor the expansion of the
surface monolayer because the HDL particles swell with the
greater influx of core CE. Therefore, the existence of larger
HDL particles in the non-CAD elderly subjects can be
attributed to the increased PLTP activity observed with the
increased transfer of PL to HDL in this group. It is
noteworthy that a positive correlation was also observed
between age and CE transfer, HDL size and HDL
cholesterol. The increase in HDL cholesterol in the absence
of apo A1 is in accordance with our hypothesis that the
cholesterol content in the HDL particles, and not the particle
number, was greater in the elderly.
The smaller amount of transfer of CE, TG, and NEC to
HDL in the group of elderly patients with CAD than in the
non-CAD subjects suggests that an increase in the transfer
of those lipids may protect against CAD. Diminution of
HDL size in elderly patients with CAD may be secondary to
the decreased lipid transfers. A diminished ability of HDL
to receive NEC may reflect disturbances in the function of
the lipoprotein; because most of the cholesterol esterification
process occurs in the HDL fraction, diminution of the NEC
influx to the lipoprotein would correspond to decreased
cholesterol esterification. As expected, the HDL cholesterol
level was lower in the CAD elderly group, and this result
may be one of the causative factors for the decreased lipid
transfers to the lipoprotein. Because of the dynamic nature
of HDL metabolism, it is difficult to hypothesize whether
the diminished influx of lipids was one of the causes of
CAD in the CAD elderly group or only a marker that
reflected the exposure of the lipoprotein to the metabolic
disturbances occurring in the disease.26 In any event, the
small number of subjects in the CAD group, as indicated by
the power analysis, may have been a limitation when
comparing that group to the non-CAD group.
In this study, PON 1 activity was not different among the
subject groups; however, the activity of this enzyme can
widely vary (up to 40-fold) in a given population because of
environmental factors and polymorphisms.27
CONCLUSION
In conclusion, our results show that in elderly subjects
who did not have CAD, the transfer of CE, the major
component of the HDL core, and PL, the main HDL surface
layer component, to HDL was higher than in younger
subjects. In elderly subjects with CAD, the transfer of CE,
TG, and NEC to HDL was decreased compared to the non-
CAD elderly subjects. Those differences were also correlated
with HDL particle size and suggest that aging is accom-
panied by changes in lipid transfer and HDL size that, in
addition to HDL cholesterol levels, could also be determi-
nants of the absence or presence of CAD in the elderly.
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